MNTA and various generic-drug companies are up today, which is somewhat surprising insofar as the FDA panel’s endorsement of NVS’ Neupogen FoB was close to being a fait accompli (#msg-109613911).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.